Lipid metabolism dysregulation underlies chronic pathologies such as obesity, diabetes and cancer. Besides their role in structure and energy storage, lipids are also important signalling molecules regulating multiple biological functions. Thus, understanding the precise lipid metabolism enzymatic steps that are altered in some pathological conditions is helpful for designing better treatment strategies. Several monoacylglycerol (MAG) species are only recently being recog- are still being discovered, indicating the complexity, Abbreviations:
| INTRODUCTION
Lipid metabolism is central to cell survival and proliferation throughout the organism as lipids are indispensable for the structural, signalling and energy needs of all cells. There are various classes of lipids depending on their structure and thus many enzymes that constitute a number of specific pathways participate in the biosynthesis and degradation of these lipids. Either genetic or acquired alteration in the expression and activities of these enzymes leads to abnormal lipid metabolism and contribute to the pathogenesis of a number of diseases, including cardiovascular abnormalities, type 2 diabetes (T2D), obesity and other associated pathologies. Glycerolipids (GL), including polar phospholipids and neutral acylglycerols, form a major pool of cellular lipids and work from our lab 1 and elsewhere 2, 3 over the past several years demonstrated the importance of GL/free fatty acid (FFA) cycle in the overall metabolism of GL and in the production of different signalling molecules. 1 GL/FFA cycle consists of lipogenesis, which initiates with the esterification of glycerol-3-phosphate (Gro3P) to form triglycerides (TG) or phospholipids (PL), and lipolysis, which is the breakdown of TG and PL to give rise to glycerol and FFA. Interestingly, several lipid metabolism enzymes localized in specific tissues and subcellular locations, particularly in the lipolytic process 4, 5 are still being discovered, indicating the complexity, Abbreviations: 2-AG, 2-arachidonoylglycerol; ABHD6, α-β-hydrolase domain 6; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ATGL, adipose triglyceride lipase; CES, carboxylesterase; CB, cannabinoid; CNS, central nervous system; DAG, diacylglycerols; EBV, Epstein-Barr virus; GL/FFA, glycerolipids/free fatty acid; Gro3P, glycerol-3-phosphate; GSIS, glucose-stimulated insulin secretion; HSL, hormone-sensitive lipase; LPA, lysophosphatidic acid; MAG, monoacylglycerol; MAGL, monoacylglycerol lipase; Munc13-1, mammalian Unc13-1; PKC, protein kinase C; PPARs, peroxisomal proliferator-activated receptors; TG, triglycerides; T2D, type 2 diabetes; TRPV1, transient receptor potential vanilloid subfamily member 1; VMH, ventromedial hypothalamus 14, 15 Interestingly, expression of ABHD6 has been shown to be highly increased in European patients with the autoimmune disease systemic lupus erythematosus (SLE) due to a single nucleotide polymorphism in the promoter region of ABHD6 gene. 16 Deletion or inhibition of ABHD6 activity has been shown to be beneficial in certain neurological diseases and cancers. [17] [18] [19] [20] Our recent work showed the importance of 1-monoacylglycerols (1-MAGs), in particular 1-MAG with saturated fatty acid group, that accumulate upon ABHD6 suppression, in the regulation of insulin secretion, insulin sensitivity and also in adipose browning via peroxisomal proliferator-activated receptor (PPAR)α and PPARγ activation. [11] [12] [13] In the present review, we focus on the recent developments on the physiological and pathological roles of ABHD6 and its substrate MAG as a cellular signalling molecule.
| Metabolism of MAG
During the digestion of ingested fats in the intestinal lumen, GL are hydrolyzed by pancreatic lipase to FFA and 2-MAG and are absorbed into the intestinal epithelial cells where they are reutilized to assemble TG and chylomicrons, which are released into circulation. 21 2-MAG produced in intestine does not cross directly into circulation. 22, 23 Once in blood, chylomicron-associated TG are degraded by lipoprotein lipases to 2,3-DAG, then to 2-MAG and finally FFA and glycerol. 24 
| Biosynthesis of MAG
There are 2 stereoisomers of MAG, depending on the position of acyl chain on the glycerol backbone, and these are 1(3)-MAG where the fatty acid is attached at sn1 or sn3 position on glycerol molecule and 2-MAG where the fatty acid is attached at the sn2 position of glycerol.
Even though it is known that 2-MAG can spontaneously isomerize to 1-MAG, which is thermodynamically more stable, the precise conditions for this are not clear. Lipolysis is the major route of MAG formation and depending on the reaction sequences and players involved, either 2-MAG or 1-MAG may be formed ( Figure 1 Besides TG, membrane-associated PL also contributes to intracellular 2-MAG (eg, 2-AG). Thus, signalling via Gq-coupled G-protein coupled receptor (GPCR) (eg, FFAR1) leads to the activation of phospholipase C on the cytosolic side of plasma membrane and hydrolysis of PL, particularly phosphoinositides, resulting in the formation of sn1,2-DAG. Plasma membrane associated sn1-DAG lipases or even cytosolic HSL can hydrolyze sn1,2-DAG to form 2-MAG and FA. Such PL-derived 2-MAG generally has an unsaturated fatty acid (for instance, arachidonic acid) at sn2 position. 33 This pathway gives rise to 2-AG in CNS and other tissues. Besides DAG hydrolysis, lysophosphatidic acid (LPA) is another possible precursor of 1-MAG. Cellular LPA comes from de novo lipogenesis, through the acylation of Gro3P, by Gro3P acyltransferase enzymes present in mitochondria or endoplasmic reticulum. 34 The action of phospholipase A2 on phosphatidic acid (PA) also yields LPA 35 ( Figure 1 ).
There are specific LPA phosphatases that hydrolyze LPA to generate MAG. 36 However, these enzymes are oriented in such a way to generate MAG either on cell outer surface or in endoplasmic reticulum lumen. 37 
| Degradation of MAG and roles of various ABHD enzymes
As there are two stereoisomers of MAG, it is important to recognize that many lipases cleave 1-MAG to FFA and glycerol readily, and not 2-MAG. 38, 39 The isomers of acylglycerols are stereochemically discriminated during lipase-dependent hydrolysis reactions and this is also influenced by the lipolytic conditions and the nature of substrate. 40 The presence of a specific lipase that hydrolyzes MAG was described initially in the intestine 41 and also in adipose tissue 42 and this protein was later purified, and identified as a 33 kDa MAGL, belonging to serine hydrolase family 43 and its cDNA was cloned. 44 MAGL was found to hydrolyze both 1-and 2-MAG species with equal rates, 45 unlike ABHD6, which shows some preference for 1-MAG. 46 MAGL is expressed in many tissues and is thought to be a house-keeping enzyme in overall lipid metabolism. 47 In brain MAGL is highly expressed and contributes significantly to 2-AG hydrolysis 48 and for the release of arachidonate, which is used for prostaglandin synthesis.
Besides MAGL, other lipases such as ABHD6 and ABHD12 are also involved in intracellular MAG degradation in many tissues. 4 The plasma membrane bound ABHD6 and ABHD12 have been proposed to be major MAG hydrolases in cells lacking significant levels of MAGL. 8, 10 Although ABHD12, which is present on the plasma mem- Notably, 2-MAG can spontaneously isomerize to 1-MAG, which is thermodynamically more stable. The last step of lipolysis is MAG degradation into glycerol and free fatty acids (FFA). Hydrolysis of 2-arachidonoylglycerol (2-AG), which is a 2-MAG, releases arachidonic acid (AA), which is the precursor for prostaglandins (PG). Finally, MAG is being implicated in several signalling functions, acting via both intracellular and cell surface receptors (blue lines), which are explained in the text.
| Other pathways of MAG utilization
Besides being hydrolyzed to glycerol and FFA, cellular MAG levels can also be regulated by diverting MAG to lipid biosynthetic pathways.
Thus, acylglycerol kinases that can phosphorylate 2-MAG and also 1-MAG to form LPA have been described in brain and other tissues. [58] [59] [60] LPA, once formed, has many biological functions and is further metabolized to phosphatidic acid and other GL. 1 At least in the intestinal enterocytes, the absorbed 2-MAG is efficiently re-acylated to sn1,2-DAG by MAG acyltransferase (MOGAT). 61, 62 Although mRNA expression of certain MOGAT isoenzymes has been described in kidney, liver and adipose tissues, 63, 64 their contribution towards utilization of MAG is not clearly documented. Moreover, cyclooxygenase-2 (COX-2) has been shown to oxygenate arachidonoyl moiety of 2-AG leading to the formation of prostaglandin H(2)glyceryl ester, which eventually gives rise to prostaglandin D(2)glyceryl ester. 65 
| Signalling functions of MAG
In addition to their role in energy storage and membrane structure, several classes of lipids are now widely accepted as intracellular signalling mediators and some (eg, sn1,2-DAG) as second messengers.
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A wide range of biological functions are known to be regulated by FFA, phosphoinositides, sphingolipids, steroids, other PL and DAG. by its biosynthesis and degradation. As mentioned before, neuronal 2-AG synthesis is achieved by membrane associated sn1-DAG lipases, whereas its degradation is regulated by MAGL at the presynaptic membranes and ABHD6 at the postsynaptic membranes, where the synthesis occurs. 72 In the neurons, 2-AG signalling through CB1
receptors lowers the neurotransmitter release by calming the stimulated neurons after excitation, thereby avoiding further cell exhaustion and neuronal cell death. 73 Activation of CB1 receptors by 2-AG has also been shown to prevent the excessive activation of glutamate receptors (AMPA receptors; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) in CNS. 74 Expression of CB2 receptor is high in various immune cells, including B lymphocytes, natural killer cells, and macrophages/monocytes, and 2-AG-mediated activation of this receptor is proposed to have anti-inflammatory effects. 75 Thus, 2-AG has been shown to inhibit the secretion of inflammatory cytokines from murine leukocytes. [76] [77] [78] [79] On the contrary, others reported the production of proinflammatory cytokines from 2-AG-treated immune cells, 80, 81 indicating pleiotropic effects by 2-AG depending on cell types and conditions. In pancreatic β-cells also 2-AG/CB1 receptor-mediated signalling has been proposed to be important in the regulation of insulin secretion, 71, 82 although the physiological relevance of this is not clear. There are several excellent reviews on 2-AG and endocannabinoid signalling and reader is referred to these reviews for detailed information. 85 The importance of Munc13-1 in insulin exocytosis is highlighted by the observations that this protein expression is downregulated in T2D patients and that its partial deletion in mice leads to islet β-cell insulin secretory defect. 86, 87 Munc13-1 possesses a C1-domain, which is similar to the C1-domains present in many protein kinase C (PKC) isoenzymes. 88 It is thought that sn1,2-DAG binds to the C1-domain of Munc13-1, similar to what is noted for PKC enzymes, although with much lower affinity, due to the presence of an occluding tryptophan residue in the binding pocket. 88 We recently showed that long-chain saturated 1-MAG species bind to the C1-domain of Munc13-1 more efficiently than DAG and activate Munc13-1, to facilitate the priming of insulin granules and consequently stimulating insulin secretion in pancreatic β-cells. PPARα is known to regulate lipid and lipoprotein metabolism in many tissues, whereas PPARγ, expressed in high levels in adipose tissue, plays major role in lipogenesis and adipocyte differentiation and also controls energy storage and homeostasis, inflammation and cytokine secretion. PPARβ/δ is ubiquitously expressed and controls overall nutrient and energy metabolism in mitochondria. [89] [90] [91] PPARs are known to be activated by a variety of lipid molecules such as fatty acids, prostaglandins, fatty acid epoxides and so on. We recently showed that 1-MAG signalling for the induction of adipose browning is mediated in part through the activation of PPARα and γ. 13 Transactivation studies showed that 1-MAG, at physiologically relevant cellular concentrations, can directly bind to the ligand binding domain of PPARα and γ, and activate these transcription factors. Surprisingly, PPARβ/δ was not found to be activated by 1-MAG. 13 
| GPR119 as a MAG-activated GPCR
The Gs-coupled GPCR GPR119, is highly expressed in pancreas, gastrointestinal tract and brain and has been shown to regulate gut hormone secretion and glucose homeostasis. ically among the MAG species tested, whereas GPR119 appears to bind 2-OG more effectively and to a lesser extent with 2-palmitoylglycerol and also with 1-OG. 101 This also raises questions as to whether there are other GPCRs that bind with other MAG species.
| MAG activation of transient receptor potential vanilloid subfamily member 1 (TRPV1)
Transient receptor potential vanilloid subfamily member 1 (TRPV1), also known as capsaicin receptor, is highly expressed in primary sensory neurons, and plays a key role in the perception of peripheral thermal and inflammatory pain. 102 There are many stimuli that lead to the activation of TRPV1 and these include acidic pH, elevated temperature, burn and this receptor has also been shown to be activated by oleoylethanolamide and anandamide. 103 
| ABHD6 expression
ABHD6 is ubiquitous with relatively high mRNA expression in liver, kidney, and ovary. 15 Murine studies showed the highest ABDH6 mRNA expression in brown adipose tissue, small intestine, and brain. 9 We have recently shown ABHD6 expression at mRNA and protein level in pancreatic islets and β-cell lines, besides liver, kidney and testis. In fact, our studies indicated that in pancreatic islet β-cells ABHD6 is the major MAG hydrolase as MAGL is expressed at much lower levels. 12 ABHD6 has been identified as a key enzymatic regulator of endocannabinoid signalling with high expression in the brain. 2, 4, 81 Unlike other lipases, very little is known about the regulation of ABHD6 expression and activity. ABHD6 upregulation in the small intestine and liver following high-fat feeding was reported, although the precise mechanism is not known. 9 The possibility of peripheral tissue and cell-specific role of ABHD6 in regulating physiological functions came to light from studies showing its impact on insulin secretion in β-cells, 12 in the control of white adipose tissue browning, 13 and also in macrophage-mediated inflammation. 10 Moreover, differential expression of ABHD6 has been implicated in pathological conditions, such as malignancies, 14 ,15 which will be reviewed in the following sections.
Although MAGL and ABHD6 share same catalytic activity for the breakdown of MAG, ABHD6 inhibition does not affect MAGL function in the brain 4, 8, 110 and selective deletion of ABHD6 in peripheral tissues, with antisense oligonucleotides (ASOs), has no effect on hepatic MAGL activity or expression. 9 Similarly, global deletion of MAGL has no compensatory effect on ABHD6, ABHD12 or HSL expression in brain, liver and adipose tissue. 7 These results suggest that MAGL and ABHD6 being present in different subcellular locations do not compensate for each other's activity and likely have different physiological roles, as in the case of the separate synaptic location of these enzymes for the control of 2-AG levels. 
| Substrates of ABHD6
Consistent with its ubiquitous expression and the different studies showing multiple functions for ABHD6 depending on its tissue and cellular localization, ABHD6 may control the cellular levels of not only MAG (eg, 2-AG) but also other lipidic substrates. 2-AG was the first physiological substrate identified for ABHD6, 4, 8 followed by the recognition that this enzyme acts on other MAG species also with various pathophysiological implications. [11] [12] [13] 46 In addition, ABHD6 was found to hydrolyze lysophospholipids, including lysophosphatidylcholine, 9 LPA, 9 and bis(monoacylglycero)phosphate (BMP), which is enriched in late endosomes/lysosomes. 113 Because of its activity on BMP, ABHD6 is suggested to participate in the late endosomal/lysosomal lipid sorting machinery. 113 Whether ABHD6 acts on other metabolites needs being investigated using discovery based unbiased (untargeted) LC-MS/MS approaches.
| ABHD6 inhibitors
A limited number of ABHD6 inhibitors have been reported (Table 1) , with varying specificity and many of these are covalent inhibitors. In 2007, the Cravatt group identified WWL70 as a potent and selective carbamate-based ABHD6 inhibitor. 114 Recombinant human ABHD6
in cell extracts was found to be strongly inhibited by WWL70 with an IC50 of 55 nM, 115 which is comparable to the previously 70 nM value, determined in COS-7 cells expressing recombinant human ABHD6, by using competitive activity-based protein profiling. 114 An analoge of WWL70, WWL123 with better brain penetrance was later described. 116 Triazole urea-based compounds such as KT195 with much higher potency to inhibit ABHD6 were later reported by the Cravatt group. 117 However, we showed that all these ABHD6 inhibitors are also inhibitory to CES-1 and other enzymes at higher concentrations. 115 Other inhibitors of ABHD6 include JZP-430, which inhibits human ABHD6 with an IC50 of 44 nM and limited off-target activity 118 and KT203, another triazole urea type inhibitor with very high potency. 119 Several DAG lipase inhibitors were also found to inhibit ABHD6. 120, 121 The summary of ABHD6 biochemical characterization is shown in Table 1 .
| Physiological and pathological roles of ABHD6
Although ABHD6 is best studied in endocannabinoid signalling in the CNS, several recent studies implicated ABHD6 in many other physiological functions in peripheral tissues, including inflammation, insulin secretion, adipose tissue browning and energy homeostasis (Figure 2 ).
| Inflammation and autoimmune diseases
During "acute inflammation," inflammatory macrophages and other immune cells play essential role in the defense against pathogens;
however, a sustained inflammatory response mediated by cytokines and reactive oxygen/nitrogen species can harm the host tissues.
Impaired lipid metabolism is a hallmark of chronic metabolic diseases, which are also associated with "low-grade inflammation" and inflammatory polarization of macrophages and T lymphocytes. 122 Hydrolysis of 2-AG by ABHD6 releases arachidonic acid, the precursor for prostaglandins, some of which contribute to inflammatory processes. 123 Pharmacological blockade of ABHD6 in macrophages has been reported to increase the COX-2-mediated synthesis of prostaglandin-D2-glycerol ester (PGD2-GE), which has antiinflammatory effects both in vitro and in vivo. 10 It has been suggested that blockade of ABHD6, which is present at much higher levels in microglia/macrophages, can increase 2-AG/CB2R signalling in microglia/macrophages specifically, but not in T cells, and exert antiinflammatory effects. 18 2-AG/CB2R signalling has also been shown to prevent CXCL12 induced chemotaxis in activated T-lymphocytes, thus controlling their immune actions.
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In ABHD6-KO mice fed high fat diet which introduces inflammatory conditions, circulating FGF and FGF21, which have antiinflammatory properties, were found to be elevated, whereas the inflammatory cytokines/peptides such as ICAM-1, resistin and oncostatin were lowered, indicating the anti-inflammatory effects of ABHD6 deletion. 13 Inhibition of ABHD6 was suggested as a candidate therapeutic strategy for the treatment of multiple sclerosis 18 and other neurodegenerative diseases. 20 Thus, the enhancement of 2-AG/CB receptor signalling and the reduced production of the inflammatory agents upon ABHD6 inhibition have been suggested to contribute to the therapeutic effect of WWL70 in these diseases. 18, 20 Also, expression of ABHD6 was found to be elevated greatly in European patients with systemic lupus erythematosus (SLE), an autoimmune disease. 16 The same study also reported that an SNP variant with lower ABHD6 expression is in fact protective against SLE.
All these studies implicate ABHD6 as a potential player in the regulation of inflammatory pathways and autoimmunity.
| Insulin secretion
Glucose-stimulated insulin secretion (GSIS) in pancreatic β-cells is an essential physiological process responsible for the control of glucose homeostasis and overall nutrient metabolism in several tissues. Decades of research revealed the significance of the closure of K-ATP channels by ATP and a lowering in ADP caused by enhanced glucose metabolism in β-cells, to trigger Ca 2+ influx, which is needed for insulin granule fusion with plasma membrane and eventual exocytosis of insulin. 125 Amplification pathways of the Ca 2+ signal, involving in particular intracellular lipid metabolism and GL/FFA cycle in the β-cell, have been shown to play essential role in insulin secretion. 126, 127 We recently provided ample evidence that 1-MAG generated near plasma membrane in β-cell during glucose metabolism acts as a signalling molecule linking glucose metabolism to insulin secretion by facilitating insulin granule exocytosis. We showed that ABHD6 negatively controls insulin secretion by hydrolyzing the metabolic signal, 1-MAG. 12 It was observed that 1-MAG directly binds and activates the exocytosis facilitating protein, Munc13-1, which helps in secretory granule fusion with plasma membrane 12 ( Figure 3 ). Furthermore, whole body and β-cell-specific deletion of ABHD6 in mice led to enhanced GSIS both in vivo and in islets ex vivo, thus indicating a major role for ABHD6 in GSIS regulation in β-cells. 11, 12 Results from β-cell-specific ABHD6-KO mice provided evidence that ABHD6 accessible MAG is implicated not only in glucose signalling but also in the control of insulin secretion promoted by various fuel secretagogues and non-fuel stimuli such as neurohormonal agonists.
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It is important to note that many inhibitors of ABHD6 as well as MAGL are not exclusively specific and do show off-target inhibitory effects and thus results from their use need to be interpreted cautiously. Thus, it was shown that MAGL inhibition with URB602, which is a highly non-specific inhibitor, 128, 129 was found to enhance 2-AG levels and insulin secretion in MIN6 β-cells and isolated human islets. 130 In a recent study, it was argued that MAGL also regulates insulin secretion from INS-1(832/13) cells and isolated rat islets. 131 These authors showed that pharmacological inhibition of MAGL led to decrease, but not increase in GSIS. 131 However, because of high concentrations of the inhibitors used in their study the possibility of inhibition of other lipases such as HSL that produces MAG and unspecific effects, cannot be eliminated. By contrast we showed that inhibition of MAGL activity using lower doses of a pharmacological agent or via siRNA knockdown of the enzyme does not alter GSIS in β-cells.
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Overall, there is much evidence implicating ABHD6 and 1-MAG in the control of GSIS both in vivo and in isolated β-cells and rodent islets. Also, pharmacological inhibition of ABHD6 can be of therapeutic significance in restoring optimal GSIS response of β-cells in T2D
conditions. In this respect, administration of the ABHD6 inhibitor WWL70 to low-dose streptozotocin-treated mice, a model of lean T2D with reduced β-cell mass, was shown to restore normal glucose tolerance and GSIS. Obesity is a major risk factor for insulin resistance, cardiometabolic diseases and T2D. 132 Thus, it is important to understand the underlying metabolic disturbances, particularly in lipid metabolism that contribute to the development of obesity and associated complications. Depot-specific functions of adipose tissue are well known and thus white adipose (visceral and subcutaneous) is important for storing fat, whereas brown fat is responsible for non-shivering thermogenesis by burning fat and other nutrients. 133 It is known that under appropriate stimulatory conditions, white adipocytes assume "brown-like" morphology and adapt certain oxidative functions of brown adipose tissue and this process is known as "browning" and these adipocytes are called "beige or brite" adipocytes. 134 It has been suggested that enhanced energy expenditure and thermogenesis is an attractive mechanism by which obesity and associated metabolic disorders could be curtailed. 135 Thermogenesis is a specific metabolic function of brown adipocytes and beige adipocytes that is accomplished in part via uncoupling protein-1 (UCP1), by uncoupling mitochondrial oxidative phosphorylation, leading to energy dissipation as heat. Thus, non-ATP yielding burning of fuels in brown/beige adipose mitochondria causes thermogenesis, which allows mammals to maintain their body temperature. 136 Besides the well-appreciated white adipose browning agents, such as catecholamines, triidothyronine, FGF21, bone morphogenic proteins 137 and adenosine, 138 certain lipid-based mediators such as prostaglandins and alkyl-ethers have also been shown to be involved in this process. 137 We recently showed that GL/FFA cycle derived 1-MAG likely plays an important role in brown adipose activation, beige adipose formation and energy expenditure. 13 We reported that ABHD6 inhibition or deletion in preadipocytes leads to cell-autonomous browning during their differentiation, as evidenced by the elevated expression of brown adipose markers including UCP1, PGC1α and so on. Whole-body ABHD6-KO mice, when fed a high fat diet, are protected from obesity, insulin resistance, glucose intolerance, hyperinsulinemia, hepatic steatosis, and have elevated energy expenditure, which was attributable in part to increased white adipose browning and brown adipose tissue activation. 13 In the knockout mice fed high-fat diet, many genes associated with brown adipose tissue function and those responsible for adipocyte browning in the visceral fat were induced. PPARs are key regulators of adipocyte metabolism and beige adipocyte formation 139 and brown adipose tissue activation. 133 We found that 1-MAGs accumulate in white and brown adipose tissues in ABHD6-KO mice, and that both PPARα and γ, which are important for brown adipose functionality, are activated by 1-MAG, by direct binding to the ligand binding domain. 13 In fact, PPARα antagonism in vivo, was found to counteract the ABHD6-KO-mediated effects on adipose browning and thermogenic programme and other beneficial effects, strongly implicating adipose tissue ABHD6 and 1-MAG in the overall regulation of adipose functionality and whole body energy metabolism. The fact that MAGL deletion under high fat feeding lacked any effect on adipose browning or brown adipose tissue activation, 7 emphasizes the key role of ABHD6 and its substrate 1-MAG, in adipose tissue metabolism and function, whole body energy metabolism and obesity.
Besides regulating adipose function, ABHD6 also appears to be important in other peripheral tissues as ABHD6 deletion was found to curtail hepatic steatosis and enhance insulin independent glucose uptake in muscle and adipose tissues. 9, 13 Thomas et al 9 employing first restoring whole body insulin sensitivity, ABHD6 deletion in fact lowers insulin secretion and thus hyperinsulinemia under these conditions. 13 Thus, ABHD6 suppression appears to have several beneficial effects against complications associated with diet-induced obesity and metabolic syndrome (Figure 4 ) and to the extent we observed, many of these effects are mediated via signalling by 1-MAG.
| Endocannabinoid signalling and neurotransmission in the CNS
Pharmacological blockade of ABHD6 in a genetic seizure model has been documented to exert anti-epileptic effects in mice. 19 Also, ABHD6 selective inhibition was found to be neuroprotective and beneficial in mouse models of traumatic brain injury 20 and multiple sclerosis. 18 Chronic MAGL inhibition causes 2-AG overload, which desensitizes the 2-AG-CB1 receptor signalling axis in specific brain regions, leading to undesirable side effects, such as hypomobility and hyperreflexia. 72, 140 However, partial inhibition of 2-AG hydrolysis in the CNS, by targeting ABHD6, is probably beneficial in avoiding CB receptor desensitization and behavioural tolerance and therefore it should be tested whether development of selective ABHD6 inhibitors can provide a valid approach for the treatment of neuroinflammatory and neurodegenerative diseases. higher VMH 2-AG levels in conditions of endocannabinoid recruitment and fail to adapt to various metabolic challenges. 141 These mice with VMH ABHD6 deficiency were characterized by an impaired feeding response to fasting, reduced cold induced thermogenesis and increased susceptibility to hypothermia, resistance to diet-induced weight loss (transition from high fat diet to regular chow) and increased susceptibility to high fat diet-induced obesity. Thus, VMH ABHD6 appears to play key role in mediating energy metabolism flexibility because it is involved in the counter-regulatory responses to major metabolic shifts, including fasting, nutrient excess, cold and dieting. 141 Hence, ABHD6 is expected to play important actions in whole body energy balance via its actions in the CNS and its respective roles in various brain areas need to be defined.
| Malignancies
ABHD6 was identified as a target gene for Epstein-Barr virus (EBV) nuclear antigen 2, which is involved in EBV-associated malignancies Gro3P levels are regulated via its hydrolysis by the newly identified glycerol-3-phosphate phosphatase in the cytosol. The concentration of 1-MAG produced in the vicinity of the plasma membrane is controlled by the membrane bound ABHD6 to produce glycerol and FFA, which can leave the cell. 1-MAG generated close to the plasma membrane, binds and activates Munc13-1, an exocytosis facilitating and insulin secretory vesicle priming protein, which enhances insulin granule fusion with the plasma membrane and the release of insulin. DHAP, dihydroxyacetone phosphate.
such as endemic Burkitt's lymphoma, Hodgkin's lymphoma and posttransplant lymphoma. 142 Differential expression of ABHD6 was observed in tumour cells, with extremely high level of expression in U2OS (bone), 15 PC-3 (prostate) 15 and Jurkat (leukocyte) 15 and in Ewing tumours. 14 One of the most fatal cancers with high rate of metastasis is pancreatic ductal adenocarcinoma (PDAC). 143 ABHD6
was found to be highly expressed in mouse and human PDAC tumours and cell lines, and ABHD6 inhibitors were able to reduce cancer cell proliferation in vitro, and tumour metastasis in vivo.
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Interestingly, ABHD6 substrate, 2-AG was found to have antiinvasive properties in prostate carcinoma, but only the endogenous 2-AG, but not the exogenous 2-AG. 144 Moreover, MAGL was also found to be elevated in some malignancies. 145, 146 Finally, based on RNAseq data and screening of differential genes in liver tumours, ABHD6 was found to be a potential marker of hepatocellular carcinoma prognosis. 147 Further research is required to better characterize the role of ABHD6 in development, growth and apoptosis of tumour cells, and its use as a potential diagnostic marker and a therapeutic target for the treatment of certain malignancies ( Figure 4 ). 
| CONCLUSION

